Nathan Jessop

Nathan Jessop is a columnist for Pharmaceutical Technology Europe.


Taxing Times for French Pharma

While French politics has taken a decisive shift to the left with the election of the country’s first socialist president for 17 years

2012 A Good Bad and Ugly Year for France's Servier

Whichever way you look at it, 2012 will be a dramatic year for Servier. The French company has a number of collaborations that could lead to a new generation of products, but any positive news from these developments is likely to be overshadowed by the ongoing safety scandal of its diabetes treatment Mediator (benfluorex hydrochloride).